AVEO Pharmaceuticals (AVEO Pharmaceuticals) FCF Margin % : 0.64% (As of Sep. 2022)

View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. AVEO Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2022 was $0.19 Mil. AVEO Pharmaceuticals's Revenue for the three months ended in Sep. 2022 was $30.45 Mil. Therefore, AVEO Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2022 was 0.64%.

As of today, AVEO Pharmaceuticals's current FCF Yield % is -4.38%.

The historical rank and industry rank for AVEO Pharmaceuticals's FCF Margin % or its related term are showing as below:

AVEO' s FCF Margin % Range Over the Past 10 Years
Min: -24.03 Med: 0 Max: 0
Current: -24.03

AVEO's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -148.24 vs AVEO: -24.03

AVEO Pharmaceuticals FCF Margin % Historical Data

The historical data trend for AVEO Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals FCF Margin % Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

FCF Margin %

Get a 7-Day Free Trial

-252.86

-462.67

-10.14

-637.08

-135.38

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
FCF Margin %	Get a 7-Day Free Trial															-53.20	-69.05	-39.29	-9.69	0.64

Competitive Comparison of AVEO Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, AVEO Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVEO Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's FCF Margin % falls into.

AVEO Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

AVEO Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-57.257	/	42.295
	=	-135.38 %

AVEO Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2022 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	0.194	/	30.449
	=	0.64 %

AVEO Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

Executives

Jebediah Ledell	officer: Chief Operating Officer	C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey	director, officer: President & CEO	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso	officer: Chief Commercial Officer	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell	10 percent owner
Growth Equity Opportunities Iv, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera	officer: Chief Financial Officer	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring	director	AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202